Table 2.

Clinical follow-up data of patients enrolled in the study. For each patient, pre- and post-treatment CA125 values, response scores following Response Evaluation Criteria in Solid Tumors (RECIST) guideline parameters and % of killing after in vitro cisplatinum-based treatment were reported. Values of CA-125 are expressed as UI/l. Notes: np = not present; CDDP = cisplatinum.

Patient Code	CA125 Pre-Treatment	CA125 Post-Treatment (3rd Cycle)	CA125 Post-Treatment (End)	Response Score	% Killing (CDDP 5 μg/mL)
					FN	HA
1	490	16	278	−1	49.80	47.90
2	168	6	<35	2	50.47	39.99
3	649	171	<35	1	78.52	74.40
4	108	23	<35	2	86.51	55.11
5	1116	32	<35	2	35.79	48.64
6	118	45	<35	0	37.17	51.51
7	7172	457	45	1	45.76	43.81
8	20	np	<35	2	96.06	77.62
9	290	13	8	1	91.30	66.16
10	1232	625.9		−1	57.76	1.55
11	16	np	8.3	2	53.14	0.00
12	3175	43	58	1	71.83	52.40
13	70	6.5	5.6	2	36.61	32.60